Chinese Medical Journal · 2015 · 38 citations · 18 references
MedicineEndocrinologyOncologyEndocrine Nuclear MedicineOncologic SurgerySurgical OncologyEndocrine Tumor PrognosisPreoperative Oncology AssessmentRisk StratificationThyroid CancerThyroid ImagingThyroid SurgeryAdjuvant Radioiodine TherapyDifferentiated Thyroid Cancer DiagnosisInitial Risk AssessmentRadioiodine ScanningRadioiodine Therapy PlanningRecurrence Risk EstimationScreening Risk StratificationThyroid Cancer Risk
BACKGROUND: Postoperative preablative stimulated thyroglobulin (ps-Tg) has been evaluated in predicting prognosis and success of ablation regarding differentiated thyroid cancer (DTC); however, its relationship with recurrence risk and radioiodine decision-making remains uncertain, especially in Chinese DTC patients. We aimed to evaluate the association between ps-Tg and recurrence risk stratification in DTC, to provide incremental values for ps-Tg in postoperative assessment and radioiodine management. METHODS: Seven hundred and seven patients with DTC were included; low-risk (L; n = 90), intermediate-risk (I; n = 283), and high-risk (H; n = 334, 117 with distant metastasis [M1]) patients were divided according to recurrence risk stratification. The M1 group was further analyzed regarding evidence of metastasis. Cut-off values of ps-Tg were obtained using receiver operating characteristic analysis. RESULTS: Patients with more advanced disease at initial risk stratification were more likely to have higher ps-Tg levels (I vs. L: P < 0.05; H vs. I: P < 0.001; H vs. L: P < 0.001). The corresponding cut-off value of ps-Tg for distinguishing sensitivity and specificity in each of the two groups was 2.95 ng/ml (I vs. L: 61.5%, 63.3%), 29.5 ng/ml (H vs. I: 41.9%, 92.6%), 47.1 ng/ml (M1 vs. M0 in the H group: 79.5%, 88.9%) and 47.1 ng/ml (M1 vs. M0 in all patients: 79.5%, 93.7%). With the cut-off value at 47.1 ng/ml, ps-Tg was the only factor that could be used to identify distant metastases, and consequently if measured before radioiodine therapy would prevent 10.26% of patients with M1 from undertreatment. CONCLUSIONS: Ps-Tg, as an ongoing reassessment marker, favors differential recurrence risk grading and provides incremental values for radioiodine treatment decision-making.
18
Scott A. Hundahl, Irvin D. Fleming, Amy M. Fremgen et al. · Cancer · 1998 · 1.8K citations · Full text
Medicine, Oncology, Cancer Control +16
R. Michael Tuttle, Hernán Tala, Jatin P. Shah et al. · Thyroid · 2010 · 933 citations · Full text